NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
CourtTariffsAnnouncesFebruaryCasesCrisisTrumpChallengeNewsDigestTimelineMajorHealthCaseCovid-19ReportingDailyAnnouncementMilitaryParacetamolPublicExpandedTargetingIncluding
CourtTariffsAnnouncesFebruaryCasesCrisisTrumpChallengeNewsDigestTimelineMajorHealthCaseCovid-19ReportingDailyAnnouncementMilitaryParacetamolPublicExpandedTargetingIncluding
All Articles
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24 , 2026
manilatimes.net
Published about 3 hours ago

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24 , 2026

manilatimes.net · Feb 23, 2026 · Collected from GDELT

Summary

Published: 20260223T220000Z

Full Article

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Events” section of the MaxCyte website at https://investors.maxcyte.com/. About MaxCyte Get the latest news delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy. At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX® gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn. Investor RelationsGilmartin Group David Deuchler, CFA [email protected] Media RelationsOak Street Communications Kristen White+1 415-608-6060 [email protected]


Share this story

Read Original at manilatimes.net

Related Articles

manilatimes.netabout 4 hours ago
Myriad Genetics Reports Fourth Quarter and Full - Year 2025 Financial Results ; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Published: 20260223T214500Z

manilatimes.netabout 4 hours ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

Published: 20260223T214500Z

manilatimes.netabout 11 hours ago
Editas Medicine to Participate in Upcoming Investor Conferences

Published: 20260223T144500Z

manilatimes.net2 days ago
Quality HealthCare Opens New Flagship Clinic in Prince Building

Published: 20260222T003000Z

manilatimes.net2 days ago
AECOM and CityUHK School of Energy and Environment forge strategic partnership to accelerate Hong Kong sustainability and climate resilience goals

Published: 20260222T003000Z

manilatimes.net3 days ago
Venezuela new amnesty law gets a chilly response from the opposition and detainee families

Published: 20260221T071500Z